FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Who May Qualify: - Inclusion criteria for MIBC diagnostic studies 1. Patients with suspected muscle-invasive bladder cancer; 2. Completion of FAPI PET/MRI, FDG PET/MRI and MRI; 3. Complete clinical laboratory and pathological data. - Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study 1. Patients diagnosed with muscle invasive bladder cancer; 2. Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy; 3. Complete clinical laboratory and pathological data. Who Should NOT Join This Trial: - Exclusion criteria for MIBC diagnostic study 1. Combined with other malignant tumors; 2. Not receiving surgical treatment; 3. Receiving neoadjuvant therapy before surgery; 4. Previous allergy to contrast components or similar components; 5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities; 6. Incomplete clinicopathological data - Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study 1. Combination of other malignant tumors; 2. FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy; 3. Prior hypersensitivity to contrast components or similar components; 4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function; 5. Incomplete clinicopathological data. Always talk to your doctor about whether this trial is right for you.